For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Survodutide: origin, structure and research history

Research Library › Incretin & Amylin

Survodutide (development code BI 456906) is an investigational, fatty-acid-modified peptide designed to activate both the glucagon receptor and the GLP-1 receptor. It originated at Zealand Pharma and has been developed by Boehringer Ingelheim under a licence signed in 2011, with its discovery pharmacology published in 2022. As of October 2026 it remains in Phase III trials and is not approved by the FDA or any other regulator.

Key facts

TypeSynthetic acylated peptide carrying a C18 fatty acid; glucagon/GLP-1 receptor dual agonist
Other namesBI 456906
Developed byZealand Pharma (origin); Boehringer Ingelheim (global development under licence)
First describedLicence and collaboration announced 2011; discovery and preclinical paper published 2022
Designed targetGlucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R)
Regulatory status (Oct 2026)Not FDA-approved; investigational, in Phase III trials (SYNCHRONIZE and LIVERAGE programs)

Who developed it

Survodutide traces back to a research partnership between the Danish peptide company Zealand Pharma and the German drugmaker Boehringer Ingelheim. In June 2011 the two companies announced an exclusive global licence and collaboration covering Zealand’s glucagon/GLP-1 dual agonists, with Boehringer Ingelheim funding research, development and commercialization [1].

Boehringer Ingelheim describes survodutide as licensed from Zealand Pharma and says it is solely responsible for the compound’s global development, while Zealand keeps co-promotion rights in the Nordic countries [3, 5].

Structure and design

Survodutide belongs to a class of engineered peptides modeled on the dual receptor activity of oxyntomodulin, a naturally occurring gut hormone that interacts with both the glucagon and GLP-1 receptors. A 2022 paper by Boehringer Ingelheim scientists, with GLP-1 researcher Daniel Drucker among the co-authors, described BI 456906 as an acylated peptide carrying a C18 fatty acid, a modification intended to extend its half-life [2].

The same paper reported cell-based assays and mouse studies designed to confirm engagement of each receptor separately, including experiments in GLP-1 receptor knockout mice [2]. These describe the designed mechanism in preclinical settings only.

Research history

  • 2011: Zealand Pharma and Boehringer Ingelheim announce their licence and collaboration on glucagon/GLP-1 dual agonists [1]
  • 2021: FDA grants Fast Track designation in a research program on metabolic dysfunction-associated steatohepatitis (MASH) [3]
  • 2022: Discovery and preclinical pharmacology of BI 456906 published in Molecular Metabolism [2]
  • 2023: Phase III SYNCHRONIZE program announced, including SYNCHRONIZE-1, SYNCHRONIZE-2 and a cardiovascular outcomes study; EMA accepts the compound into its PRIME scheme [3, 4]
  • 2024: FDA Breakthrough Therapy designation in the MASH program; Phase III LIVERAGE and LIVERAGE-Cirrhosis trials begin [3]
  • June 2026: Results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD presented at the American Diabetes Association Scientific Sessions [5]

Regulatory status as of October 2026

Survodutide is an investigational compound. It is not approved by the FDA, the European Medicines Agency or any other regulator, and Boehringer Ingelheim’s June 2026 release continued to describe it as investigational and not approved [5]. Its Phase III programs span overweight and obesity (SYNCHRONIZE) and MASH (LIVERAGE).

The regulatory designations it has received, including FDA Fast Track (2021), FDA Breakthrough Therapy (2024), EMA PRIME (2023) and a Breakthrough Therapy designation from China’s NMPA (2024), relate to the MASH program. Designations of this kind speed up development and review; they are not approvals [3, 5].

In August 2026 the FDA issued warning letters to several online sellers of peptides labeled “research use only,” and survodutide was among the products named in those letters [6].

About this reference page

Kalibra Labs does not currently supply Survodutide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Who makes survodutide?

Survodutide originated at Zealand Pharma and is being developed by Boehringer Ingelheim, which licensed it in 2011 and holds global development responsibility [1, 5].

Is survodutide FDA approved?

No. As of October 2026 survodutide is investigational and in Phase III trials; it is not approved by the FDA or any other regulator [5].

What is BI 456906?

BI 456906 is the Boehringer Ingelheim development code for survodutide, an acylated peptide designed to activate both the glucagon and GLP-1 receptors [2].

What phase is survodutide in?

It is in Phase III. The SYNCHRONIZE trials began in 2023 and the LIVERAGE trials in 2024 [3, 4].

Has the FDA taken action on unapproved survodutide?

Yes. Survodutide was among the products named in FDA warning letters sent to online “research use only” peptide sellers in August 2026 [6].

Sources

  1. Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to advance novel compounds (company announcement via FierceBiotech), 16 Jun 2011. Link
  2. Zimmermann T, Thomas L, Baader-Pagler T, et al., Augustin R. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. doi:10.1016/j.molmet.2022.101633. Link
  3. Boehringer Ingelheim. Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide. Press release, 8 Oct 2024. Link
  4. Pharmaphorum. Boehringer moves obesity therapy into phase 3. 6 Oct 2023. Link
  5. Boehringer Ingelheim. Press release on survodutide Phase III SYNCHRONIZE-1 and SYNCHRONIZE-MASLD data at ADA 2026, 7 Jun 2026 (via PharmaShots Newswire). Link
  6. ArentFox Schiff. RUO-ined: Five peptide vendors learn that 'research use only' is not a legal strategy. 18 Sep 2026. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top